The second report described a FLT3-ITD-positive, BCR-ABL-negative CML patient in blast crisis, who acquired the mutation A848P at relapse after a 9-month response to alternating therapy with sunitinib and sorafenib (165). This evidence concerns the gene FLT3 and chronic myelogenous leukemia, BCR-ABL1 positive.